WHAT IS CLAIMED IS:

1. Use of methylone (3,4-methylenedioxy-N-methylcathinone) in the manufacture of a pharmaceutical composition for treating and/or preventing a neuropsychiatric illness and/or ameliorating a symptom thereof in a subject in need thereof.

2. Use of MBDB (N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane) in the manufacture of a pharmaceutical composition for treating and/or preventing a neuropsychiatric illness and/or ameliorating a symptom thereof in a subject in need thereof.

3. Use of 2C-B (4-Bromo-2,5-dimethoxyphenethylamine) in the manufacture of a pharmaceutical composition for treating and/or preventing a neuropsychiatric illness and/or ameliorating a symptom thereof in a subject in need thereof

4. The use according to any of claims 1 to 3, wherein the neuropsychiatric illness is a depressive disorder or post-traumatic stress disorder (PTSD).

5. The use according to claim 1 or claim 2, wherein the neuropsychiatric illness is an anxiety disorder.

6. The use according to claim 1 or claim 3, wherein the neuropsychiatric illness is fibromyalgia.

7. The use according to claim 1, wherein the neuropsychiatric illness is acute stress disorder, a personality disorder (PD), a mood disorder, or an eating disorder.

8. The use according to claim 3, wherein the neuropsychiatric illness is a somatic symptom disorder.

9. The use according to any of claims 1-8, wherein the methylone, MBDB, or 2C-B is to be administered in a dose of 5-250 mg, or in a dose of 0.08-4 mg/kg.

10. The use according to any of claims 1-8, wherein the methylone, MBDB, or 2C-B is to be administered once per week, or is to be administered more than once per week, for example, twice per week, three times per week, four times per week, five times per week, or six times per week.

11. The use according to any of claims 1-8, wherein the neuropsychiatric illness is treatment-resistant.

12. The use according to any of claims 1-8, wherein the subject is suicidal.

13. The use according to any of claims 1-8, wherein the methylone, MBDB, or 2C-B is used in combination with an additional therapy for the neuropsychiatric illness, for example

wherein the additional therapy is psychotherapy, or wherein the additional therapy comprises one or more additional psychoactive agents to be administered to the subject.

14. The use according to claim 13, wherein the additional psychoactive agents are selected from the selective-serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), serotonin-norepinephrine-dopamine reuptake inhibitors (SDNRIs), and anxiolytic agents,

for example wherein the additional psychoactive agent is a selective-serotonin reuptake inhibitor (SSRI) and the subject is taking or is continuing to take the SSRI concurrently with the methylone, MBDB, or 2C-B.

15. The use according to any of claims 1-8, wherein an initial dose of methylone, MBDB, or 2C-B is to be administered to the subject, which is then to be boosted 30 minutes to 4 hours later by a second methylone, MBDB, or 2C-B dose, respectively, in an amount that is about 10% -100% of the initial dose.

.